Summary of findings table ‐ Daratumumab plus standard therapy vs usual care
Progression‐free survival (PSF) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower progression‐free survival (at 24 months) compared with standard therapy (moderate certainty).
1 finding from 1 review
- Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple… 2024 · Cochrane Headline outcomes onlyHR 0.48 [0.39, 0.58]3 studies · 1663 participantsModerate